Last reviewed · How we verify
Cell-based therapy
At a glance
| Generic name | Cell-based therapy |
|---|---|
| Sponsor | Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Hypertension
- Diarrhoea
- Procedural hypotension
- Muscle spasms
- Bronchitis
- Cough
- Urinary tract infection
- Constipation
- Nasopharyngitis
- Arteriovenous fistula site complication
- Back pain
- Upper respiratory tract infection
Key clinical trials
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (PHASE2)
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- FAP-targeted PET/NIR in Lung Malignant Tumors
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |